The World Market for Gynaecology

Summary

Spectra's World Market for Gynaecology, 2007-2017 provides a unique assessment of current developments and prospective factors that will shape the global female health market over the next decade. This unrivalled, in-depth market research study commissioned by one of the top three multinational pharmaceutical companies presents a detailed and comprehensive analysis of prescription products used in the diverse areas of infertility, contraception, gynaecological disorders, and menopause.

The market for gynaecology is predicated on hormonal drugs that have recently been subject to controversy based on reports of associated increased risks of cardiovascular disease and cancer. The global market has suffered as a consequence due to cautious prescribing approaches for hormone replacement therapies.

The pipeline however is vast with over 75 hormonal products in clinical development that will offer purer analogues, low-dose formulations, new delivery modes and formats, novel mechanisms of action, and which also confer sophisticated clinical effects over traditional products.

The market for gynaecology is showing signs of a significant upward growth trend over the forecast period to 2017 and the next decade will be exciting, but companies will need to differentiate their products and consider the market forces that may affect product revenue and portfolios.

The World Market for Gynaceology aims to provide an expert analysis of the prescription drug market for female health over the next decade based on current industrial insights, market factors and forces, and trend information. Study objectives include critical assessments of existing products, reviews of products in clinical development, therapy forecasting of product/portfolios to 2017, and market sector analytics by therapeutic category and discrete disorder.

Report Highlights And Key Findings

• Commissioned by a market leader in Women's and Sexual Health, this report uniquely provides a comprehensive analysis of current and pipeline gynaecology products, which is not available elsewhere in the market literature;
• Provides a concise overview of the conditions and diseases related to gynaecology including aetiology, epidemiology, and management;
• Complete description of existing products to include reviews of product characteristics, side effects, and sales performance;
• Extensive information on new gynaecological drugs in the pipeline, including product characteristics, technologies, research status, and the results of clinical trials;
• Market analysis of the US and international markets for gynaecological prescription products with therapy area and sales forecasts to 2017;
• Analysis of market dynamics for infertility, contraception, menstrual and gynaecological disorders, and menopause;
• Product-focused appraisals and discussions for market potential and growth;
• Benchmark analytics for current research themes and future therapy areas;
• Evaluation of the key drivers and predictors of growth and innovation in gynaecology;
• In-depth assessment of the commercial and drug development opportunities in the field.
• Reports on the status of existing and pipeline gynaecology prescription products to 2017;
• Highlights the drug development strategies that are being employed by companies to sustain leadership;
• Provides a comprehensive description of gynaecological and obstetric drugs currently on the market;
• Describes the pipelines and biological targets being pursued by a host of companies, both small and large;
• Assists in analysing discovery programmes of competitors and aids decision-making for in-house research and development;
• Provides critical information on how companies are reformulating hormonal drugs to solve market, clinical, and regulatory barriers;
• Provides market trend data of best- and least-performing gynaecology products;
• Identifies niche markets where there is an unmet need for gynaecological and obstetric therapeutics;
• Provides forecasts of products, therapy areas, and drug classes to 2017;
• Shows estimation of the global market for gynaecology to include both hormonal and nonhormonal products.

What Can I Learn From This Report?

• The current armamentarium of gynaecology drugs including their advantages and disadvantages;
• New hormonal and nonhormonal drugs in the pipeline and their mechanisms and product characteristics;
• What gynaecological conditions represent the most important market sectors over the next decade;
• Trend information for use of gynaecological products during the next 10 years;
• Which gynaecological and obstetric drugs are currently competing with each other for the same indications;
• How companies are expanding indications and reformulating their best-selling products;
• Which products are destined for significant growth and market success;
• Therapy areas forecasts and individual product sales estimates to 2017;
• What niches of the gynaecology market are likely to provide high-growth sector opportunities;
• Which classes of drugs are on course for major drug development;
• Why some new formulations are likely to be attractive to patients and physicians;
• How novel therapeutics might compete with traditional products in the global market.

Content